Home
University of Bergen
Rakel Brendsdal Forthun's picture

Rakel Brendsdal Forthun

Staff Engineer
Department of Clinical Science
Home Page
  • E-mailRakel.Forthun@uib.no
  • Phone+47 55 58 45 11+47 414 59 638
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
    Room 
    Armauer Hansens hus, rom 008
  • Postal Address
    Postboks 7804
    5020 Bergen

My main field of interest is proteomic analyses of novel therapeutic combinations for the treatment of Acute Myeloid Leukemia (AML). In this project, my main focus is to find new drugs and chemicals that can complement and increase the anti-leukemic effect of valproic acid, and to discover the mechanisms behind this effect.

Academic article
  • Show author(s) (2022). Novel hybridization- and tag-based error-corrected method for sensitive ctDNA mutation detection using ion semiconductor sequencing. Scientific Reports. 10 pages.
  • Show author(s) (2021). KRAS mutation analysis by droplet digital PCR of duodenal juice from patients with MODY8 and other pancreatic diseases. Pancreatology (Print). 1460-1465.
  • Show author(s) (2020). Partial response to sorafenib in a child with a myeloid/lymphoid neoplasm, eosinophilia, and a ZMYM2-FLT3 fusion. Journal of Pediatric Hematology/Oncology. 1-4.
  • Show author(s) (2019). ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Scientific Reports. 1-15.
  • Show author(s) (2019). Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 1729-1749.
  • Show author(s) (2019). High constitutive cytokine release by primary human acute myeloid leukemia cells is associated with a specific intercellular communication phenotype. Journal of Clinical Medicine.
  • Show author(s) (2017). Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. Journal of Proteomics. 32-41.
  • Show author(s) (2017). Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer. 1-13.
  • Show author(s) (2016). The past, present and future subclassification of patients with acute Myeloid Leukemia. Current Pharmaceutical Biotechnology. 6-19.
  • Show author(s) (2016). Global cell proteome profiling, phospho-signaling and quantitative proteomics for identification of new biomarkers in acute myeloid leukemia patients. Current Pharmaceutical Biotechnology. 52-70.
  • Show author(s) (2012). Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 910-917.
  • Show author(s) (2012). Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLOS ONE.
Letter to the editor
  • Show author(s) (2021). Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line. British Journal of Haematology. 415-427.
Doctoral dissertation
  • Show author(s) (2012). Phosphoproteomics in disease stratification and therapy design of acute myeloid leukemia.
Abstract
  • Show author(s) (2008). Evaluation of combinational therapy of MDM2-antagonist nutlin-3 and HDAC-inhibitor valproic acid in acute myeloid leukemia in vitro and in vivo. Blood. 1024-1024.
Poster
  • Show author(s) (2017). combination of interferon-alpha and valproic acid in acute myeloid leukemia cells in vitro and in vivo.
Academic literature review
  • Show author(s) (2021). Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System . Cancers. 17 pages.
  • Show author(s) (2014). Heat shock protein 90 – a potential target in the treatment of human acute myelogenous leukemia. Advances in cancer drug targets. 3-53.
  • Show author(s) (2010). Clinical proteomics of myeloid leukemia. Genome Medicine.

More information in national current research information system (CRIStin)

Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid.

Forthun RB, Sengupta T, Skjeldam HK, Lindvall JM, McCormack E, Gjertsen BT, Nilsen H.

PLoS One. 2012

 

Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.

McCormack E, Haaland I, Venås G, Forthun RB, Huseby S, Gausdal G, Knappskog S, Micklem DR, Lorens JB, Bruserud O, Gjertsen BT.

Leukemia. 2012

 

Clinical proteomics of myeloid leukemia.

Hjelle SM, Forthun RB, Haaland I, Reikvam H, Sjøholt G, Bruserud O, Gjertsen BT.

Genome Med. 2010

 

 

• Master degree in medical cell biology, "A phosphoproteomic study of the Theophylline-Valproic acid-ATRA combination therapy in the BNML rat model" 2008

• PhD, "Phosphoproteomics in disease stratification and therapy design of acute myeloid leukemia", 2012